These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 16340836)

  • 1. [Mesothelioma: advances in chemotherapy].
    Jacoulet P
    Rev Mal Respir; 2005 Dec; 22(6 Pt 2):8S49-54. PubMed ID: 16340836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
    Tomek S; Manegold C
    Lung Cancer; 2004 Aug; 45 Suppl 1():S103-19. PubMed ID: 15261443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in chemotherapy for lung cancer].
    Ono A; Yamamoto N
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1475-81. PubMed ID: 18799900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural mesothelioma: medical treatment update.
    Vorobiof DA; Mafafo K
    Clin Lung Cancer; 2009 Mar; 10(2):112-7. PubMed ID: 19362954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pemetrexed].
    Sudoh J; Gemma A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing first-line treatment options for patients with advanced NSCLC.
    Wakelee H; Belani CP
    Oncologist; 2005; 10 Suppl 3():1-10. PubMed ID: 16368866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed in first-line treatment of non-small cell lung cancer.
    Esteban E; Casillas M; Cassinello A
    Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategy for treatment of metastatic non-small cell lung cancer.
    Berhoune M; Banu E; Scotte F; Prognon P; Oudard S; Bonan B
    Ann Pharmacother; 2008 Nov; 42(11):1640-52. PubMed ID: 18957625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
    Reck M; Heigener DF; Gatzemeier U
    Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
    Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments.
    Catalano A; Gianni W; Procopio A
    Crit Rev Oncol Hematol; 2004 May; 50(2):101-9. PubMed ID: 15157659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
    Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
    J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Second-line treatment and targeted therapy of advanced lung cancer].
    Nakamura Y; Yamamoto N
    Gan To Kagaku Ryoho; 2009 May; 36(5):710-6. PubMed ID: 19461168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.